Dr Sasha Bakhru says 108 BioCapital’s $20 million investment into Pinwheel Therapeutics will fund a Phase 2b trial of Ciraparantag, a late stage anticoagulant reversal asset. India, February 5, 2026: Pinwheel Therapeutics, a clinical stage biopharmaceutical company developing differentiated therapeutic assets, has raised $20 million from US based growth equity firm 108 BioCapital. The capital … Continue reading A Universal Anticoagulant Reversal Therapy Moves Closer to Late Stage Trials with Fresh Capital